Carbosilane dendrimers with phosphonium terminal groups are low toxic non-viral transfection vectors for siRNA cell delivery

Publication date: Available online 13 March 2019Source: International Journal of PharmaceuticsAuthor(s): Regina Herma, Dominika Wrobel, Michaela Liegertová, Monika Müllerová, Tomáš Strašák, Marek Maly, Alena Semerádtová, Marcel Štofik, Dietmar Appelhans, Jan MalyAbstractNon-viral gene delivery vectors studied in the gene therapy applications are often designed with the cationic nitrogen containing groups necessary for binding and cell release of nucleic acids. Disadvantage is a relatively high toxicity which restricts the in vivo use of such nanoparticles. Here we show, that the 3rd generation carbosilane dendrimers possessing (trimethyl)phosphonium (PMe3) groups on their periphery were able to effectively deliver the functional siRNA into the cells (B14, Cricetulus griseus), release it into the cytosol and finally to achieve up to 40% gene silencing of targeted gene (glyceraldehyde-3-phosphate dehydrogenase (GAPDH)) with the comparable or, in some cases, even better effectivity as their ammonium counterparts. Moreover, such cationic dendrimers show relatively low in vivo toxicity as compared to their ammonium analogues when analyzed by standard Fish Embryo Test (FET) on Danio rerio in vivo model, with LD50 = 6.26 µM after 48 hours of incubation. This is more than 10-fold improvement as compared to published values for various other types of cationic dendrimers. We discuss the potential of further incre...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research

Related Links:

The condition was stopped in mice by blocking a protein that fuels brain inflammation. The Arizona team are hopeful it will lead to a gene therapy to combat tinnitus and other hearing loss disorders.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Novartis said it plans to price its recently approved gene therapy at $2.125 million, making it the world’s most expensive medicine. Novartis slaps $2M-plus pricetag on newly approved gene therapy Zolgensma—and cost watchdogs approve Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma—and just how payers would cover the "transformative" spinal muscular atrophy trea...
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Topics in Healthcare Source Type: forums
Authors: Chen R, Ren L, Cai Q, Zou Y, Fu Q, Ma Y Abstract Over the last decade, stem cells have drawn extensive attention from scientists due to their full potential in tissue engineering, gene therapy, and cell therapy. Adipose-derived stem cells (ADSCs), which represent one type of mesenchymal stem cell (MSC), hold great promise in bone tissue engineering due to their painless collection procedure, their ability to self-renew and their multi-lineage differentiation properties. Major epigenetic mechanisms, which involve DNA methylation, histone modifications and RNA interference (RNAi), are known to represent one ...
Source: Connective Tissue Research - Category: Research Tags: Connect Tissue Res Source Type: research
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Internal Medicine News Source Type: news
ConclusionDiamond –Blackfan anemia is a rare disease that carries significant morbidity and mortality if not diagnosed early and managed appropriately. Limited health resources, patient registries, and specialists as seen in developing countries result in a paucity of knowledge about Diamond–Blackfan anemia in Af rica. This case reminds clinicians about Diamond–Blackfan anemia as a cause for anemia in infants, the limitations in making the diagnosis in under-resourced health care systems, and the need for standardized treatment protocols applicable to resource-limited countries.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
(Mary Ann Liebert, Inc./Genetic Engineering News) A therapeutic gene delivered into the spinal canal of infant rhesus monkeys was still being expressed after nearly 4 years, with no evidence of acute or chronic neuronal tox-icity, according to a new study published in Human Gene Therapy.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Cancer Gene Therapy, Published online: 17 June 2019; doi:10.1038/s41417-019-0115-9Prognostic value of the FUT family in acute myeloid leukemia
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Cancer Gene Therapy, Published online: 17 June 2019; doi:10.1038/s41417-019-0114-xA chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Human Gene Therapy, Ahead of Print.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
AbstractMucopolysaccharidoses (MPS) are inborn errors of metabolism produced by a deficiency of one of the enzymes involved in the degradation of glycosaminoglycans (GAGs). Although taken separately, each type is rare. As a group, MPS are relatively frequent, with an overall estimated incidence of around 1 in 20,000 –25,000 births. Development of therapeutic options for MPS, including hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT), has modified the natural history of many MPS types. In spite of the improvement in some tissues and organs, significant challenges remain unsol ved, in...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Fish | Gene Therapy | Genetics | Nanotechnology | Nutrition | Toxicology